JAVIER IGNACIO
MUÑOZ GONZÁLEZ
Forscher in der Zeit 2015-2019
![Foto de JAVIER IGNACIO](/img/nophoto.png)
![Foto de Complejo Hospitalario de Toledo](/img/noimage_org.png)
Complejo Hospitalario de Toledo
Toledo, EspañaPublikationen in Zusammenarbeit mit Forschern von Complejo Hospitalario de Toledo (19)
2024
-
Clinical impact of the TPSAB1 genotype in mast cell diseases: A REMA study in a cohort of 959 individuals
Allergy: European Journal of Allergy and Clinical Immunology, Vol. 79, Núm. 3, pp. 711-723
2023
-
Bone and Cytokine Markers Associated With Bone Disease in Systemic Mastocytosis
Journal of Allergy and Clinical Immunology: In Practice, Vol. 11, Núm. 5, pp. 1536-1547
-
Mast Cell Activation Syndromes: Comparison Between Two Scoring Models to Predict for Mast Cell Clonality
The journal of allergy and clinical immunology. In practice, Vol. 11, Núm. 3, pp. 908-919
2022
-
Altered innate immune profile in blood of systemic mastocytosis patients
Clinical and Translational Allergy, Vol. 12, Núm. 6
-
Comprehensive Analysis of Acquired Genetic Variants and Their Prognostic Impact in Systemic Mastocytosis
Cancers, Vol. 14, Núm. 10
-
Frequency and prognostic impact of blood-circulating tumor mast cells in mastocytosis
Blood, Vol. 139, Núm. 4, pp. 572-583
2021
-
Genome-wide association study identifies novel susceptibility loci for KIT D816V positive mastocytosis
American Journal of Human Genetics, Vol. 108, Núm. 2, pp. 284-294
-
Pathogenic and diagnostic relevance of KIT in primary mast cell activation disorders
Annals of Allergy, Asthma and Immunology, Vol. 127, Núm. 4, pp. 427-434
-
Proposed global prognostic score for systemic mastocytosis: a retrospective prognostic modelling study
The Lancet Haematology, Vol. 8, Núm. 3, pp. e194-e204
-
Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal
HemaSphere, Vol. 5, Núm. 11, pp. E646
2019
-
Bone marrow mast cell antibody-targetable cell surface protein expression profiles in systemic mastocytosis
International Journal of Molecular Sciences, Vol. 20, Núm. 3
-
Frequency and prognostic impact of KIT and other genetic variants in indolent systemic mastocytosis
Blood, Vol. 134, Núm. 5, pp. 456-468
-
Mars: Mutation-adjusted risk score for advanced systemic mastocytosis
Journal of Clinical Oncology, Vol. 37, Núm. 31, pp. 2846-2856
2018
-
Characterization of CD34 + hematopoietic cells in systemic mastocytosis: Potential role in disease dissemination
Allergy: European Journal of Allergy and Clinical Immunology, Vol. 73, Núm. 6, pp. 1294-1304
-
Impact of somatic and germline mutations on the outcome of systemic mastocytosis
Blood Advances, Vol. 2, Núm. 21, pp. 2814-2828
2017
-
Imatinib in systemic mastocytosis: a phase IV clinical trial in patients lacking exon 17 KIT mutations and review of the literature
Oncotarget, Vol. 8, Núm. 40, pp. 68950-68963
2016
-
Increased IL6 plasma levels in indolent systemic mastocytosis patients are associated with high risk of disease progression
Leukemia, Vol. 30, Núm. 1, pp. 124-130
-
KIT D816V-mutated bone marrow mesenchymal stem cells in indolent systemic mastocytosis are associated with disease progression
Blood, Vol. 127, Núm. 6, pp. 761-768
2015
-
Detection of the KIT D816V mutation in peripheral blood of systemic mastocytosis: Diagnostic implications
Modern Pathology, Vol. 28, Núm. 8, pp. 1138-1149